Growth Of Tumors Already Established By Tobacco Carcinogens Promoted By Nicotine
Main Category: Smoking / Quit SmokingAlso Included In: Cancer / Oncology
Article Date: 24 Jul 2006 - 21:00 PDT
| Patient / Public: | ![]() |
|
| Healthcare Prof: | ![]() |
1 (1 votes) |
While it is established that nicotine by itself is not carcinogenic, researchers have now shown that nicotine promotes cell proliferation and the progression of tumors already initiated by tobacco carcinogens. In a study by Srikumar Chellappan and colleagues from the University of South Florida appearing online on July 20 in advance of print publication in the August issue of the Journal of Clinical Investigation, the authors show that the presence of receptors that bind nicotine, known as nicotinic acetylcholine receptors (nAChRs), on bronchial cells as well as lung cancer cells are key to nicotine-induced cell proliferation of lung cancer cells.
nAChRs function mainly in the neuronal system, however recent studies have shown their expression and function in non-neuronal systems as well. In the current study, the authors show that stimulation of human non-small cell lung cancers (NSCLCs) as well as cells lining the air passages of the lung (known as bronchial cells) with a physiological concentration of nicotine leads to robust cell proliferation that is dependent on nAChRs.
Furthermore, nicotine appears to activate the major components of the cell proliferation cycle in a manner very reminiscent of growth factors. Specifically, nicotine stimulation leads to the binding of Raf-1 to Rb, activation of cyclin-dependent kinases, phosphorylation of Rb, and recruitment of E2F1 to proliferative promoters.
Previous studies had shown that interfering with the interaction of Rb and Raf-1 prevented cell growth and tumor growth. In the current study the same appears to be true for nicotine stimulation of cells. A role for the Rb-Raf-1 interaction in the genesis of lung cancer is further supported by the observation that there was more Raf-1 associated with Rb in 8 out of 10 tumor samples examined, compared to the adjacent normal tissues. These observations suggest a role for Rb-Raf-1 interaction in the genesis of lung cancer.
These studies shed new light on the previously unknown mechanisms underlying nicotine-induced cell proliferation in lung cancer cells - namely that functional nAChRs on bronchial cells as well as lung carcinoma cells enable nicotine to promote the growth of established tumors.
###
TITLE: Nicotine induces cell proliferation by beta-arrestin-mediated activation of Src and Rb-Raf-1 pathways
AUTHOR CONTACT:
Srikumar Chellappan
University of South Florida, Tampa, Florida, USA.
E-mail: ChellaSP@moffitt.usf.edu.
View the PDF of this article at: http://https://www.the-jci.org/article.php?id=28164
Contact: Brooke Grindlinger
Journal of Clinical Investigation
Visit our smoking / quit smoking section for the latest news on this subject.
MLA
14 Feb. 2012. <http://www.medicalnewstoday.com/releases/47844.php>
APA
http://www.medicalnewstoday.com/releases/47844.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.






